Fig. 2: Estimated rate pf pCR with ganetespib versus the concurrent HER2-negative control.

Final pCR probability distributions in ganetespib (red) and control (blue) arms, for A All HER2-negative participants, B HR-negative/HER2-negative participants, and C HR-positive/HER2-negative participants.